Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 11/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 11/20 | 0.35 |
| ▸ | BIRC3 | Q13489 | 7/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113164 | 0.88 | XIAP (0.43) | XIAPBIRC2BIRC3RAB9ACYP2C9 | |
| SCHEMBL2114216 | 0.88 | EPHX2 (0.40) | XIAPBIRC2BIRC3NPC1RAB9A | |
| SCHEMBL2114000 | 0.87 | XIAP (0.38) | XIAPBIRC2BIRC3 | |
| SCHEMBL2115163 | 0.87 | XIAP (0.42) | XIAPBIRC2BIRC3CYP3A4CYP2C9 | |
| SCHEMBL2113710 | 0.85 | XIAP (0.44) | XIAP | |
| SCHEMBL2115895 | 0.85 | XIAP (0.45) | XIAPBIRC2BIRC3CYP3A4CYP2C9 | |
| SCHEMBL2116478 | 0.84 | EPHX2 (0.41) | XIAPBIRC2BIRC3NPC1RAB9A | |
| SCHEMBL2113472 | 0.84 | XIAP (0.36) | XIAPBIRC2BIRC3CYP3A4CYP2C9 | |
| SCHEMBL2113800 | 0.84 | XIAP (0.35) | XIAPBIRC2BIRC3CYP3A4CYP2C9 | |
| SCHEMBL2115164 | 0.84 | EPHX2 (0.41) | XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885BIRC2 4/4885BIRC3 5/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885BIRC2 4/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.